Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Pfizer to buy antibiotics business from AstraZeneca for $725 mn
BackBack

Pfizer to buy antibiotics business from AstraZeneca for $725 mn

Pfizer is buying rights to several of AstraZeneca's experimental and approved antibiotics in global markets outside the US

The transaction will give Pfizer rights to three medicines already on the market, including Zavicefta, which is used to treat severe bacterial infections resistant to other drugs. Photo: BloombergPremium
The transaction will give Pfizer rights to three medicines already on the market, including Zavicefta, which is used to treat severe bacterial infections resistant to other drugs. Photo: Bloomberg

Hong Kong/London: Pfizer Inc. agreed to buy an antibiotics business from AstraZeneca Plc for $725 million as well as other payouts, settling for one piece of a company it once tried to acquire.

Pfizer will pay $550 million to AstraZeneca when the transaction closes and make another payment of $175 million in January 2019, according to a statement on Wednesday. In addition, AstraZeneca is eligible to receive as much as $250 million in milestone payments, up to $600 million in sales-related payments, as well as certain royalties.

New York-based Pfizer has been looking for ways to bolster its pipeline after two failed attempts at a major acquisition, first with AstraZeneca in 2014, then with Allergan Plc this year. The US drug maker this week agreed to buy Medivation Inc. in a $14 billion deal.

AstraZeneca, meanwhile, has been shoring up its declining revenue by selling off products that aren’t central to its business, enabling investment in focus areas like cancer research. The London-based drug maker in June sold its anaesthetics medicines, another non-essential area, to Aspen Pharmacare Holdings Ltd. Revenue from such “externalization", as the company calls it, was $1.1 billion last year, and AstraZeneca has said it would generate more than that this year.

Severe infections

Shares of AstraZeneca fell 0.7% to 5,027 pence as of 8.56am. The stock has risen 8.9% this year. Pfizer closed on Tuesday in New York at $35.09 a share, up 0.7%.

Pfizer is buying rights to several of AstraZeneca’s experimental and approved antibiotics in global markets outside the US, including Zavicefta, which is used to treat severe bacterial infections resistant to other drugs—an area of growing need.

The transaction will give Pfizer rights to three medicines already on the market, including Zavicefta, which was approved by the European Commission in June. It also gives Pfizer two drugs that are still in clinical development, including one to treat methicillin-resistant staphylococcus, or MRSA, infections.

AstraZeneca’s portfolio will add to more than 60 anti-infective and anti-fungal medicines that Pfizer sells, said John Young, group president at Pfizer Essential Health, in the statement.

AstraZeneca is “pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases", said Luke Miels, executive vice-president for Europe, in the statement.

The deal doesn’t include biotechnology products in development at AstraZeneca’s MedImmune unit, or AstraZeneca’s stake in Entasis Therapeutics, a company developing new small-molecule anti-infectives. Bloomberg

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 24 Aug 2016, 04:08 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie